

GOLDENBERG DAVID M  
Form 4  
August 28, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
GOLDENBERG DAVID M

(Last) (First) (Middle)

C/O IMMUNOMEDICS, INC, 300  
THE AMERICAN ROAD

(Street)

MORRIS PLAINS, NJ 07950

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

IMMUNOMEDICS INC [IMMU]

3. Date of Earliest Transaction (Month/Day/Year)

08/24/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

See Remarks

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| Common Stock                    |                                      |  |                                |   | \$ 2,410,489<br>(1)   | D  |   |
| Common Stock                    | 08/24/2017                           |  | S                              | 25,000 D  | \$ 10.2442<br>(2) (3) \$ 3,430,578  | I  | See Footnote (4)                                      |
| Common Stock                    | 08/28/2017                           |  | S                              | 5,000 D   | \$ 11.45 \$ 3,425,578   | I  | See Footnote (4)                                      |
| Common Stock                    | 08/28/2017                           |  | S                              | 10,000 D  | \$ 11.5591<br>(3) (5) 3,415,578   | I  | See Footnote (4)                                      |



## Edgar Filing: GOLDENBERG DAVID M - Form 4

reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.

(5) The price in column 4 is a weighted average price. The prices actually received in this transaction range from \$11.55 to \$11.59.

### **Remarks:**

Chief Scientific Officer and Chief Patent Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.